Introduction to Epithelial Mesenchymal Transition (EMT)
EMT is thought to be a marker of tumor progression, with tumors that express mesenchymal markers having a greater tendency to be invasive and metastasize than those tumors only expressing epithelial markers. Tumors expressing mesenchymal markers are thought to have a worse prognosis than tumors expressing epithelial markers.
OSI’s Oncology research is focused on understanding the science of EMT in solid tumors in order to develop effective and safe mechanism-based therapeutic agents.
Common Questions:
(Click on each question to learn more)
- Why is OSI focusing their Oncology research on understanding the biology of EMT?
- What is EMT?
- What is the role of EMT in cancer progression?
- Does the EMT-status of a tumor impact response to erlotinib?
- How could the understanding of EMT science impact the development and use of Molecular Targeted Therapies?
- Is IGR-1R a cancer target?
- Is mTOR a cancer target?
- Where can I find more information on EMT?
Epithelial Mesenchymal Transition Presentation
For more information on Molecular Targeted Therapies in EMT, please contact Medical Information. |
OSI Oncology is proud to sponsor the AACR Special Conferences Series on "EMT and Cancer Prevention and Treatment" to be held from February 28-March 2, 2010 in Arlington, Virginia.
Learn more*EMT
Our research organization is focused on the discovery of novel small molecule compounds targeted against the underlying molecular mechanisms of the pathogenesis of cancer. Our strategy is to develop mechanism-based approaches to drug discovery directed at the processes underlying the role of the Epithelial Mesenchymal Transition (EMT) in the development of cancer.
Learn more*This website is not endorsed by OSI, and OSI is not responsible for its content.